Physician profile
Michael E Jackson
NPI 1912991019
$73,679.27
in general payments reported to CMS, 2019-2025
37 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $7,069 · 2021: $15K · 2022: $5,833 · 2023: $2,726 · 2024: $6,103 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,616 · Consulting Fee: $3,480 · Education: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,615.55 |
| Consulting Fee | $3,480.00 |
| Education | $422.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $23,013.61 | 2019-2025 | Winlevi |
| Pfizer INC. | $15,559.01 | 2019-2024 | |
| Almirall LLC | $11,858.34 | 2019-2025 | Seysara |
| Galderma Laboratories, L.P. | $8,566.56 | 2019-2025 | Aklief, Oracea, Twyneo |
| Dermavant Sciences, INC. | $4,640.60 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $1,721.66 | 2019-2025 | Tremfya, Simponi Aria |
| Medimetriks Pharmaceuticals, INC. | $1,148.49 | 2019-2023 | Neo-Synalar |
| Mayne Pharma Commercial LLC | $1,095.36 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $999.55 | 2019-2025 | Duobrii, Jublia, Arazlo |
| Leo Pharma INC. | $682.08 | 2019-2025 | Anzupgo, Adbry |
| Journey Medical Corporation | $517.21 | 2019-2025 | |
| Epi Health, LLC | $492.11 | 2019-2022 | |
| Incyte Corporation | $415.52 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $365.79 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $296.11 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $231.68 | 2024-2025 | Bimzelx |
| Organon LLC | $216.04 | 2025 | Vtama |
| Genzyme Corporation | $212.15 | 2020-2025 | |
| Sandoz INC. | $202.20 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $198.87 | 2020-2024 | Dupixent |
| Encore Dermatology INC. | $162.93 | 2019-2020 | |
| Abbvie INC. | $146.64 | 2019-2025 | |
| Botanix Sb INC | $139.09 | 2025 | Sofdra |
| Lilly USA, LLC | $124.61 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Sanofi-Aventis U.S. LLC | $99.99 | 2020 | |
| Novartis Pharmaceuticals Corporation | $95.97 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $82.55 | 2022-2023 | Sotyktu |
| Sebela Pharmaceuticals INC. | $73.42 | 2019-2022 | |
| Taro Pharmaceuticals USA, INC. | $67.21 | 2019 | |
| Promius Pharma LLC | $66.26 | 2019 | |
| Prugen, INC. Pharmaceuticals | $63.28 | 2019-2020 | |
| Dermira, INC. | $37.57 | 2019 | |
| Biofrontera INC. | $28.78 | 2021 | |
| Merz North America, INC. | $16.19 | 2019 | |
| Aclaris Therapeutics, INC. | $14.53 | 2019 | |
| Celgene Corporation | $13.82 | 2019 | |
| Novum Pharma, LLC | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.